aegis equites research price target $0.08

Here is a new research report about CER from www.shareAnalysis.com;

1H10 Profit result, still high risk
Restructuring is the next step in CER's return from oblivion. Price target of $0.08.

Given CER's distressed capital position, we believe a highly dilutive equity injection will be required at some point in the future. Coupled with a lack of distributions into the foreseeable future, potential long-term capital gains are speculative. CER still faces a class action, which may become very costly. CER remains a speculative proposition unsuitable for main-stream investors. SELL.

Fundamental View
CER's risk level remains very high and we advise investors to remain focused on other more predictable, investment-grade opportunities. We view a short-term equity injection is likely, SELL retained.